Genmab — Oktober 2018

[Helge_LarsenPI-redaktør]

Just a moment...

(www.proinvestor.com)

[jkj]

Dax fut. falder over 1 % Putin truer europa i missilstrid.

[jkj]

Jesus

[JKY_VH]

har han kigget for dybt i vodkaflasken?

[transalp]

Det næste bliver vel at han 'will build a wall'... hvordan mon vi er havnet her, med to historieløse idioter...

[jkj]

Det passer fint pensionisten, kursen lukker med et plus på 1.03 futten viser lige nu plus 0,5, det vil betyde -0,53 imorgen lige nu.

[jkj]

DAX Futures | Xetra DAX Futures - Investing.com

Live DAX futures prices & pre-market data including DAX futures charts, news, analysis & more DAX futures coverage.

Investing.com (www.investing.com)

[jkj]

dax fut. viser åbning på -2,4 % jeg kan ikke finde nyheder der skulle understøtte dette, men det kræves vel hellere ikke i dette marked.

[jkj]

Det er tilsyneladende dårlige end ventet resultater fra Alphabet og Amazon, der spreder skræk efter US børsluk.

[Solsen]

Måske er det blot fordi det er fredag.

[Plimsoller]

God morgen

[Helge_LarsenPI-redaktør]

God morgen.

[Plimsoller]

Så er smileyen tilbage hos Helge. Det lover godt for dagens marked

[Plimsoller]

[E_L]

from Seattle Genetics earnings report:

[E_L]

Tisotumab Vedotin (TV) Program Highlights
•Phase 1/2 Data Presented at ESMO: Seattle Genetics and Genmabreported updated data from the cervical cancer expansion cohort of theinnovaTV 201 phase 1/2 trial at the European Society for MedicalOncology 2018 Congress. The data continue to support the rationale forthe ongoing potentially pivotal trial, innovaTV 204, evaluating TV asmonotherapy for patients with recurrent and/or metastatic cervicalcancer who have relapsed or progressed after standard of

[E_L]

of caretreatment.
•InnovaTV 208 Phase 2 trial in Ovarian Cancer: Seattle Geneticsand Genmab plan to evaluate the safety and activity of TV asmonotherapy in patients with platinum-resistant ovarian cancer. Thetrial is expected to begin by early 2019.

[E_L]

from Earnings Conference Call Transcript: https://www.fool.com/earnings/call-transcripts/2018/10/26/seattle-genetics-inc-sgen-q3-2018-earnings-confere.aspx

[E_L]

Now I'll turn to Tisotumab Vedotin or TV which we're developing with Genmab. TV targets tissue factor which is expressed in a wide array of solid tumors. We are currently enrolling a pivotal trial of TV in cervical cancer that is designed to support a regulatory submission on to the FDA's accelerated approval pathway.

[E_L]

We're also enrolling a Phase 2 basket trial evaluating TV and other solid tumors where tissue factor is expressed. These include colorectal, pancreatic, non-small cell lung cancer and head and neck cancer, and we also plan to initiate a trial focused on ovarian cancer.